Drug major Lupin today said it has received USFDA's approval to market Clobetasol Propionate spray, used for treating plaque psoriasis, in the American market.
Lupin's product is a generic version of Galderma Laboratories LP's Clobex, which is indicated for treatment of moderate to severe plaque psoriasis.
As per sales data, the spray had annual sales of around USD 30.5 million in the US.
Shares of Lupin, a Mumbai-based company, today ended 1.37 per cent up at Rs 749.90 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
